COLLEGE STATION, TX / ACCESSWIRE / July 20, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (“Enzolytics” and the ‘Company’) announces the signing of a Letter of Intent (LOI) with Creative Biolabs (“Creative”) (https://www.creative-biolabs.com) to complete the joint production and commercialization of HTLV-1 monoclonal antibodies by combining the technologies of the companies. There are no effective vaccines against HTLV-1 and no antiviral drugs available for treating infections caused by the virus.
The technologies of Enzolytics and Creative will be combined to achieve the objective of production and commercialization of HTLV-1 monoclonal antibodies in the following way.
Through the application of Enzolytics’ proprietary Artificial Intelligence (AI) methodology, the Company has identified conserved immutable target sites on the HTLV-1 virus. The Company will produce targeted anti-HTLV-1 monoclonal antibodies (mAbs) in its lab at Texas A&M University’s Institute for Precli
Enzolytics Announces the Signing of a Letter of Intent with Creative Biolabs, Inc for Licensing and Commercialization of anti-HTLV-1 Monoclonal Antibodies
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Enzolytics Announces the Signing of a Letter of Intent with Creative Biolabs, Inc for Licensing and Commercialization of anti-HTLV-1 Monoclonal Antibodies
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Pets of the Week | ClarksvilleNow com
clarksvillenow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from clarksvillenow.com Daily Mail and Mail on Sunday newspapers.